ROCEED PNGS

93rd Annual Meeting

Applicant: Abbott Laboratories
Examiner: Luktor, Duid
Exhibit 2(a)

93rd Annual Meeting of the American Association for Cancer Research

San Francisco, CA • April 6-10, 2002 Volume 43 • March 2002

CONTENTS

(Arranged by Subject Category)

ABSTRACT SESSIONSPAGECell and Tumor Biology (continued)PAGECarcinogenesis (CG)Intracellular Signaling III: Protein Serine Threonine Kinase372Tumor Promotion and Progression I1Mouse Models of Cancer485Expression Analysis in Human Carcinogenesis134Molecular Mechanisms of Angiogenesis: Role ofAnimal Models I167Tumor-Host Interaction499Animal Models of Hormonally Regulated Cancers312Anti-Angiogenic Therapy521DNA Adducts: Formation and Identification343Apoptotic Machinery and Cancer527Signal Transduction I349Degradative Enzymes in Invasion533Curiongen Metabolism688Transcription Factor Functions545Translesion Synthesis and Mutagenesis694Tumor Angiogenesis: Novel Molecular and Functional Insights656Base Excision Repair and Carcinogenesis826Growth Factors/Signaling Regulation of Tumor ProgressionAnimal Models II858and Metastasis672Oxidative Stress864Death Receptors II: Fas, TNF-α, Death Domains and Cancer706DNA Repair and Cancer1025Predictive and Prognostic Factors712Environmental Carcinogenesis I1031Receptor Signaling II: EGFR/ERBR/Breast Cancer718Environmental Carcinogenesis II1037Receptors: Targets for Therapy723Tumor Markers and Detection of Micrometastasis729Receptors: Targets for TherapyNovel Targets for Antiangiogenic Therapy842Apoptosis, Cancer, and Tre				
Regulation of Metastasis-Related Gene Expression 377 Tumor Promotion and Progression I 1 Mouse Models of Cancer 485 Expression Analysis in Human Carcinogenesis 134 Molecular Mechanisms of Angiogenesis: Role of 167 Tumor-Host Interaction 499 Animal Models of Hormonally Regulated Cancers 312 Anti-Angiogenic Therapy 521 DNA Adducts: Formation and Identification 343 Apoptotic Machinery and Cancer 527 Signal Transduction I 349 Degradative Enzymes in Invasion 533 Tumor Promotion and Progression II 515 Regulation of Invasion 539 Carcinogen Metabolism 688 Transcription Factor Functions 545 Translesion Synthesis and Mutagenesis 694 Tumor Angiogenesis: Novel Molecular and Functional Insights 656 Base Excision Repair and Carcinogenesis 826 Growth Factors/Signaling Regulation of Tumor Progression Animal Models II 858 and Metastasis 672 Oxidative Stress 864 Death Receptors I: TRAIL and Cancer 700 Multistage Skin Carcinogenesis 1008 Death Receptors II: Fas, TNF- α , Death Domains and Cancer 706 DNA Repair and Cancer 1025 Predictive and Prognostic Factors Cancer 718 Environmental Carcinogenesis I 1031 Receptor Signaling I: EGFR/ERBR/Breast Cancer 718 Environmental Carcinogenesis II 1037 Receptor Signaling II 723 Tumor Markers and Detection of Micrometastasis 729 Receptors: Targets for Therapy 829 Cell and Tumor Biology (BL)	ABSTRACT SESSIONS	PAGE	Cell and Tumor Biology (continued)	PAGE
Regulation of Metastasis-Related Gene Expression 377 Tumor Promotion and Progression I 1 Mouse Models of Cancer 485 Expression Analysis in Human Carcinogenesis 134 Molecular Mechanisms of Angiogenesis: Role of 167 Tumor-Host Interaction 499 Animal Models of Hormonally Regulated Cancers 312 Anti-Angiogenic Therapy 521 DNA Adducts: Formation and Identification 343 Apoptotic Machinery and Cancer 527 Signal Transduction I 349 Degradative Enzymes in Invasion 533 Tumor Promotion and Progression II 515 Regulation of Invasion 539 Carcinogen Metabolism 688 Transcription Factor Functions 545 Translesion Synthesis and Mutagenesis 694 Tumor Angiogenesis: Novel Molecular and Functional Insights 656 Base Excision Repair and Carcinogenesis 826 Growth Factors/Signaling Regulation of Tumor Progression Animal Models II 858 and Metastasis 672 Oxidative Stress 864 Death Receptors I: TRAIL and Cancer 700 Multistage Skin Carcinogenesis 1008 Death Receptors II: Fas, TNF- α , Death Domains and Cancer 706 DNA Repair and Cancer 1025 Predictive and Prognostic Factors Cancer 718 Environmental Carcinogenesis I 1031 Receptor Signaling I: EGFR/ERBR/Breast Cancer 718 Environmental Carcinogenesis II 1037 Receptor Signaling II 723 Tumor Markers and Detection of Micrometastasis 729 Receptors: Targets for Therapy 829 Cell and Tumor Biology (BL)	Carcinogenesis (CG)		Intracellular Signaling III: Protein Serine Threonine Kinase	372
Tumor Promotion and Progression I 1 1 Mouse Models of Cancer 485 Expression Analysis in Human Carcinogenesis 134 Molecular Mechanisms of Angiogenesis: Role of Animal Models I 167 Tumor-Host Interaction 499 Animal Models of Hormonally Regulated Cancers 312 Anti-Angiogenic Therapy 521 DNA Adducts: Formation and Identification 343 Apoprotic Machinery and Cancer 527 Signal Transduction I 349 Degradative Enzymes in Invasion 533 Tumor Promotion and Progression II 515 Regulation of Invasion 539 Carcinogen Metabolism 688 Transcription Factor Functions 545 Translesion Synthesis and Mutagenesis 694 Tumor Angiogenesis: Novel Molecular and Functional Insights 656 Base Excision Repair and Carcinogenesis 826 Growth Factors/Signaling Regulation of Tumor Progression 4672 Oxidative Stress 864 Death Receptors I: TRAIL and Cancer 700 Multistage Skin Carcinogenesis I 1008 Death Receptors II: Fas, TNF-\alpha, Death Domains and Cancer 706 DNA Repair and Cancer 1025 Predictive and Prognostic Factors 712 Environmental Carcinogenesis I 1031 Receptor Signaling II 723 Tumor Markers and Detection of Micrometastasis 729 Receptors: Targets for Therapy 829 Cell and Tumor Biology (BL)				377
Animal Models I Animal Models of Hormonally Regulated Cancers 312 Anti-Angiogenic Therapy 521 DNA Adducts: Formation and Identification 343 Apoptotic Machinery and Cancer 527 Signal Transduction I 349 Degradative Enzymes in Invasion 533 Tumor Promotion and Progression II 515 Regulation of Invasion 539 Carcinogen Metabolism 688 Transcription Factor Functions 545 Translesion Synthesis and Mutagenesis 694 Tumor Angiogenesis: Novel Molecular and Functional Insights 656 Base Excision Repair and Carcinogenesis 826 Growth Factors/Signaling Regulation of Tumor Progression Animal Models II 858 and Metastasis 672 Oxidative Stress 864 Death Receptors I: TRAIL and Cancer 700 Multistage Skin Carcinogenesis 1008 Death Receptors II: Fas, TNF-α, Death Domains and Cancer 706 DNA Repair and Cancer 1025 Predictive and Prognostic Factors 712 Environmental Carcinogenesis I 1031 Receptor Signaling II 723 Receptor Signaling II 723 Receptors: Targets for Therapy 829 Novel Targets for Antiangiogenic Therapy 842 Cell and Tumor Biology (BL)	Tumor Promotion and Progression I	1		: 485
Animal Models I Animal Models of Hormonally Regulated Cancers 312 Anti-Angiogenic Therapy 521 DNA Adducts: Formation and Identification 343 Apoptotic Machinery and Cancer 527 Signal Transduction I 349 Degradative Enzymes in Invasion 533 Tumor Promotion and Progression II 515 Regulation of Invasion 539 Carcinogen Metabolism 688 Transcription Factor Functions 545 Translesion Synthesis and Mutagenesis 694 Tumor Angiogenesis: Novel Molecular and Functional Insights 656 Base Excision Repair and Carcinogenesis 826 Growth Factors/Signaling Regulation of Tumor Progression Animal Models II 858 and Metastasis 672 Oxidative Stress 864 Death Receptors I: TRAIL and Cancer 700 Multistage Skin Carcinogenesis 1008 Death Receptors II: Fas, TNF-α, Death Domains and Cancer 706 DNA Repair and Cancer 1025 Predictive and Prognostic Factors 712 Environmental Carcinogenesis I 1031 Receptor Signaling II 723 Receptor Signaling II 723 Receptors: Targets for Therapy 829 Novel Targets for Antiangiogenic Therapy 842 Cell and Tumor Biology (BL)	Expression Analysis in Human Carcinogenesis	134	Molecular Mechanisms of Angiogenesis: Role of	
DNA Adducts: Formation and Identification 343 Apoptoric Machinery and Cancer 527 Signal Transduction I 349 Degradative Enzymes in Invasion 533 Tumor Promotion and Progression II 515 Regulation of Invasion 539 Carcinogen Metabolism 688 Transcription Factor Functions 545 Translesion Synthesis and Mutagenesis 694 Tumor Angiogenesis: Novel Molecular and Functional Insights 656 Base Excision Repair and Carcinogenesis 826 Growth Factors/Signaling Regulation of Tumor Progression Animal Models II 858 and Metastasis 672 Oxidative Stress 864 Death Receptors I: TRAIL and Cancer 700 Multistage Skin Carcinogenesis 1008 Death Receptors II: Fas, TNF-α, Death Domains and Cancer 706 DNA Repair and Cancer 1025 Predictive and Prognostic Factors 712 Environmental Carcinogenesis I 1031 Receptor Signaling II: EGFR/ERBR/Breast Cancer 718 Environmental Carcinogenesis II 1037 Receptor Signaling II 723 Tumor Markers and Detection of Micrometastasis 729 Receptors: Targets for Therapy 829 Cell and Tumor Biology (BL)		167		499
DNA Adducts: Formation and Identification343Apoprotic Machinery and Cancer527Signal Transduction I349Degradative Enzymes in Invasion533Tumor Promotion and Progression II515Regulation of Invasion539Carcinogen Metabolism688Transcription Factor Functions545Translesion Synthesis and Mutagenesis694Tumor Angiogenesis: Novel Molecular and Functional Insights656Base Excision Repair and Carcinogenesis826Growth Factors/Signaling Regulation of Tumor ProgressionAnimal Models II858and Metastasis672Oxidative Stress864Death Receptors I: TRAIL and Cancer700Multistage Skin Carcinogenesis1008Death Receptors II: Fas, TNF-α, Death Domains and Cancer706DNA Repair and Cancer1025Predictive and Prognostic Factors712Environmental Carcinogenesis I1031Receptor Signaling II723Environmental Carcinogenesis II1037Receptor Signaling II723Tumor Markers and Detection of Micrometastasis729Receptors: Targets for Therapy829Cell and Tumor Biology (BL)Novel Targets for Antiangiogenic Therapy842	Animal Models of Hormonally Regulated Cancers	312	Anti-Angiogenic Therapy	521
Signal Transduction I349Degradative Enzymes in Invasion533Tumor Promotion and Progression II515Regulation of Invasion539Carcinogen Metabolism688Transcription Factor Functions545Translesion Synthesis and Mutagenesis694Tumor Angiogenesis: Novel Molecular and Functional Insights656Base Excision Repair and Carcinogenesis826Growth Factors/Signaling Regulation of Tumor ProgressionAnimal Models II858and Metastasis672Oxidative Stress864Death Receptors I: TRAIL and Cancer700Multistage Skin Carcinogenesis1008Death Receptors II: Fas, TNF-α, Death Domains and Cancer706DNA Repair and Cancer1025Predictive and Prognostic Factors712Environmental Carcinogenesis I1031Receptor Signaling I: EGFR/ERBR/Breast Cancer718Environmental Carcinogenesis II1037Receptor Signaling II723Tumor Markers and Detection of Micrometastasis729Receptors: Targets for Therapy829Cell and Tumor Biology (BL)Novel Targets for Antiangiogenic Therapy842	DNA Adducts: Formation and Identification	343		527
Tumor Promotion and Progression II515Regulation of Invasion539Carcinogen Metabolism688Transcription Factor Functions545Translesion Synthesis and Mutagenesis694Tumor Angiogenesis: Novel Molecular and Functional Insights656Base Excision Repair and Carcinogenesis826Growth Factors/Signaling Regulation of Tumor ProgressionAnimal Models II858and Metastasis672Oxidative Stress864Death Receptors I: TRAIL and Cancer700Multistage Skin Carcinogenesis1008Death Receptors II: Fas, TNF-α, Death Domains and Cancer706DNA Repair and Cancer1025Predictive and Prognostic Factors712Environmental Carcinogenesis I1031Receptor Signaling I: EGFR/ERBR/Breast Cancer718Environmental Carcinogenesis II1037Receptor Signaling II723Tumor Markers and Detection of Micrometastasis729Receptors: Targets for Therapy829Novel Targets for Antiangiogenic Therapy842	Signal Transduction I	349	- ·	533
Carcinogen Metabolism 688 Transcription Factor Functions 545 Translesion Synthesis and Mutagenesis 694 Tumor Angiogenesis: Novel Molecular and Functional Insights 656 Base Excision Repair and Carcinogenesis 826 Growth Factors/Signaling Regulation of Tumor Progression Animal Models II 858 and Metastasis 672 Oxidative Stress 864 Death Receptors I: TRAIL and Cancer 700 Multistage Skin Carcinogenesis 1008 Death Receptors II: Fas, TNF-α, Death Domains and Cancer 706 DNA Repair and Cancer 1025 Predictive and Prognostic Factors 712 Environmental Carcinogenesis I 1031 Receptor Signaling I: EGFR/ERBR/Breast Cancer 718 Environmental Carcinogenesis II 1037 Receptor Signaling II 723 Tumor Markers and Detection of Micrometastasis 729 Receptors: Targets for Therapy 829 Novel Targets for Antiangiogenic Therapy 842		515		539
Translesion Synthesis and Mutagenesis Base Excision Repair and Carcinogenesis 826 Growth Factors/Signaling Regulation of Tumor Progression Animal Models II 858 and Metastasis 672 Oxidative Stress 864 Death Receptors I: TRAIL and Cancer 700 Multistage Skin Carcinogenesis 1008 Death Receptors II: Fas, TNF-α, Death Domains and Cancer 706 DNA Repair and Cancer 1025 Predictive and Prognostic Factors 712 Environmental Carcinogenesis I 1031 Receptor Signaling II 723 Receptor Signaling II 723 Tumor Markers and Detection of Micrometastasis 729 Receptors: Targets for Therapy 829 Novel Targets for Antiangiogenic Therapy 842		688		• 545
Base Excision Repair and Carcinogenesis826Growth Factors/Signaling Regulation of Tumor ProgressionAnimal Models II858and Metastasis672Oxidative Stress864Death Receptors I: TRAIL and Cancer700Multistage Skin Carcinogenesis1008Death Receptors II: Fas, TNF-α, Death Domains and Cancer706DNA Repair and Cancer1025Predictive and Prognostic Factors712Environmental Carcinogenesis I1031Receptor Signaling I: EGFR/ERBR/Breast Cancer718Environmental Carcinogenesis II1037Receptor Signaling II723Tumor Markers and Detection of Micrometastasis729Receptors: Targets for Therapy829Novel Targets for Antiangiogenic Therapy842		694		656
Animal Models II 858 and Metastasis 672 Oxidative Stress 864 Death Receptors I: TRAIL and Cancer 700 Multistage Skin Carcinogenesis 1008 Death Receptors II: Fas, TNF-α, Death Domains and Cancer 706 DNA Repair and Cancer 1025 Predictive and Prognostic Factors 712 Environmental Carcinogenesis I 1031 Receptor Signaling I: EGFR/ERBR/Breast Cancer 718 Environmental Carcinogenesis II 1037 Receptor Signaling II 723 Tumor Markers and Detection of Micrometastasis 729 Receptors: Targets for Therapy 829 Novel Targets for Antiangiogenic Therapy 842	· · · · · · · · · · · · · · · · · · ·	826		٠٠.
Multistage Skin Carcinogenesis1008Death Receptors II: Fas, TNF-α, Death Domains and Cancer706DNA Repair and Cancer1025Predictive and Prognostic Factors712Environmental Carcinogenesis I1031Receptor Signaling I: EGFR/ERBR/Breast Cancer718Environmental Carcinogenesis II1037Receptor Signaling II723Tumor Markers and Detection of Micrometastasis729Receptors: Targets for Therapy829Cell and Tumor Biology (BL)Novel Targets for Antiangiogenic Therapy842		858	· · · · · · · · · · · · · · · · · · ·	672
Multistage Skin Carcinogenesis1008Death Receptors II: Fas, TNF-α, Death Domains and Cancer706DNA Repair and Cancer1025Predictive and Prognostic Factors712Environmental Carcinogenesis I1031Receptor Signaling I: EGFR/ERBR/Breast Cancer718Environmental Carcinogenesis II1037Receptor Signaling II723Tumor Markers and Detection of Micrometastasis729Receptors: Targets for Therapy829Cell and Tumor Biology (BL)Novel Targets for Antiangiogenic Therapy842	Oxidative Stress	864	Death Receptors I: TRAIL and Cancer	700
DNA Repair and Cancer 1025 Predictive and Prognostic Factors 712 Environmental Carcinogenesis I 1031 Receptor Signaling I: EGFR/ERBR/Breast Cancer 718 Environmental Carcinogenesis II 1037 Receptor Signaling II 723 Tumor Markers and Detection of Micrometastasis 729 Receptors: Targets for Therapy 829 Novel Targets for Antiangiogenic Therapy 842	Multistage Skin Carcinogenesis	1008		706
Environmental Carcinogenesis I 1031 Receptor Signaling I: EGFR/ERBR/Breast Cancer 718 Environmental Carcinogenesis II 1037 Receptor Signaling II 723 Tumor Markers and Detection of Micrometastasis 729 Receptors: Targets for Therapy 829 Novel Targets for Antiangiogenic Therapy 842		1025		712
Environmental Carcinogenesis II 1037 Receptor Signaling II 723 Tumor Markers and Detection of Micrometastasis 729 Receptors: Targets for Therapy 829 Cell and Tumor Biology (BL) Novel Targets for Antiangiogenic Therapy 842		1031		718
Tumor Markers and Detection of Micrometastasis 729 Receptors: Targets for Therapy 829 Novel Targets for Antiangiogenic Therapy 842	<u> </u>	1037	· · · · · · · · · · · · · · · · · · ·	723
Receptors: Targets for Therapy 829 Cell and Tumor Biology (BL) Novel Targets for Antiangiogenic Therapy 842	· · · · · · · · · · · · · · · · · · ·			729
Cell and Tumor Biology (BL) Novel Targets for Antiangiogenic Therapy 842	•			829
	C.H I.T Pi-la (PI)			842
	Cell and lumor Biology (BL)			870
A	Altered Signaling Barburaya in Tipmor Progression	7		876
A C. I. D. I. T				882
determine the court of the state of the stat	the state of the s			887
Regulation of Angiogenesis 18 Apoptotic Signaling Pathways II 23 Clinical Data, Imaging, and Modeling of Angiogenesis 893				893
Tagaillation of Angloganosis				
Signaling in Angiogenesis 29 Expression Profiling of Tumor Progression and Metastasis Regulation of Invasion and Metastasis-Related Gene Expression 137 Apoptotic Signaling Pathways and Cancer 996				996
Signaling Cascades in Cancer 152 Cell Adhesion / Extracellular Matrix 1043				1043
Angiogenesis Inhibitors I 173 Cell-Cell/Cell-Matrix Interactions 1049			Cell-Cell/Cell-Matrix Interactions	1049
Angiogenesis Inhibitors II 178 Models and Imaging of Tumor Progression and Metastasis 1054				1054
T 1 1 1 C 1 T D 10 1 10 1	All the same of th	•		1061
Growth Factor Signaling I: TGF-β-Heregulin Growth Factors 184 Translational Studies in Tumor Progression 1001 Growth Factor Signaling II: Small Molecule Inhibitors/Activators 190			U	
Pr. 1			OL 1 (OTT)	
Biology and Therapy of Bone Metastasis 314 Chemistry (CH) Apoptosis 327			Chemistry (CH)	
	(Mr. 2 + C	34/	P	2.6
Total and the second se		255		_
Mechanisms of Cell Adhesion 366 Chemical Biology of Drugs and Carcinogens 383			•	

ve site are glutamine /nthetase, The prevind Gluzzz ortant in ino acids structure.

Hackett,

y gland. found at essed in breast n KGFR as been s 86% utagen kinase global atoms ted by ited by dius of nimiza-

1struct Эy. We these rosine ent to stative. ective oreast

data.

rman

ancer

eepest

nmitnd.to t can nted cture ,000 a for bout nds.

tent

ses This own ı: a yaec-the ar-ar-

·Ctin Эγ ŋg n, t-

16 31

into the central carbonyl channel of the G-tetrad and were observed to form strong electrostatic interactions with guanines. For comparison, we studied the interaction of telomestatin with the parallel-stranded G-quadruplex and found that the G-quadruplex interaction of telomestatin is more selective for the intramolecular structure. Furthermore, the molecular dynamics docking simulations are in agreement with the experimental observations and may facilitate in the rational design of new G-quadruplex-interactive agents.

#3663 The molecular structure of G-quadruplexes from human telomeric DNA repeats: Implications for the design of drugs that interfere with telomere maintenance. Gary Parkinson, Michael Lee, Gianni I. Chessar, Martin Read, and Stephen Neidle. CRC Biomolecular Structure Unit, Chester Beatty Laboratories, The Institute of Cancer Research, London, UK.

The telomerase enzyme system protects telomeric ends from attrition and damage, and plays a major role in maintaining cellular immortality. We have designed a number of small molecules that inhibit telomerase by stabilising the terminal 3' end of telomeric DNA as four-stranded DNA quadruplex structures. We have determined the crystal structures of two quadruplexes formed from telomeric repeats. One structure of is an intermolecular quadruplex from two separate 12-mer DNA strands, each containing two telomeric repeats. The second structure is formed from a single strand consisting of four telomeric repeats. in all 22 nucleotides long. Both of these quadruplexes have radically different structures compared to the prevailing assumptions, with all strands having a parallel orientation and the TTA loops being embedded within the grooves rather than at the top and bottom of the stack of G-quartets. It is notable that these features are common to both structures, giving added credibility to their existence. The grooves in the structures are best described as V-shaped indentations, with complex surfaces and patterns of charge and hydrogen bonding functionality. The overall appearance of these quadruplexes resembles a disc, with the loops swung out propeller-fashion. The structures provide insight into the folding and unfolding of telomeric DNA and for ligand binding. They also indicate new opportunities for the rational design of highly specific ligands that can exploit their unique structural characteristics and discriminate against other forms of DNA structure. Such molecules may be potent effectors of telomere maintenance destabilisation in tumor cells, regardless of whether maintenance is through telomerase or ALT pathways.

#3664 Design and studies of anti-angiogenic thalidomide analogs. Pui-Kai Li, Jiandong Shi, Min Wu, Megan Marks, Zhigen Hu, Michael Ihnat, and Chandrashkhar Kamat. College of Pharmacy, the Ohio State University, Columbus, OH, BD Biosciences, Bedford, MA, Duquesne University, Mylan School of Pharmacy, Pittsburgh, PA, and the University of Oklahoma School of Medicine, Oklahoma

Angiogenesis has recently become a primary target of anticancer therapy. It has been shown that thalidomide inhibits angiogenesis. Since the anti-angiogenic activity of thalidomide was reported recently, only limited structure-activity-relationship studies have been described. We first synthesized several hydroxy metabolites of thalidomide and found that 5-hydroxy (but not 4-hydroxy) and 1'-hydroxythalidomides exhibited higher anti-angiogenic activity than thalidomide. Substituting the glutaramide ring of thalidomide with an aromatic group leads to active analogs. Specifically, replacing the glutaramide ring with substituted aniline (2,6-diisopropylaniline) yielded an extremely active analog (2,6-diisopropylphenyl)-1H-isoindole-1,3-dione. We then synthesized eleven analogs of (2,6-diisopropylphenyl)-1H-isoindole-1,3-dione substituted at the 4 or 5 position of phthalimide ring to elucidate the importance of the substitutions in regard to anti-angiogenic activities. The anti-angiogenic activities of the compounds were first determined using an in vitro fluorescein-based cell migration assay. At 10 micromolar inhibitor concentration, thalidomide exhibited weak (21.9%) inhibitory activity of endothelial cell migration. On the contrary, (2,6-diisopropylp henyl)-1H-isoindole-1,3-dione showed 75.9% migration inhibition at the same concentration. Substitution at the 4 position of (2,6-diisopropylphenyl)-1H-isoindole-1,3-dione resulted in significant decrease (0 % - 30.4 %) in endothelial cell migration inhibition. Interestingly, substitution at the 5 position of (2,6-diisopro-Pylphenyl)-1H-isoindole-1,3-dione obtained analogs with much higher endothelial cells migration inhibitory activities (48.9 % - 90.6 %) irrespective of the nature of the substituents. Next, the anti-angiogenic activities of the compounds were tested using the in vivo chicken chorioallantoic membrane (CAM) assay. We observed a direct correlation on the results obtained between the cell migration and the CAM assays. In conclusion, potent analogs of thalidomide can be obtained with modifications on phthalimide or glutarimide ring.

#3665 Thrombospondin-1 mimetic peptides as inhibitors of angiogenesis. Fortuna Haviv, Michael Bradley, Douglas Kalvin, Andrew Schneider, Sandra Majest, Randy Bell, Donald Davidson, Catherine Haskell, Kennan Marsh, Bach Nguyen, Rae D. Record, Jason Hodde, Stephen F. Badylak, Yi-Chun Wang, David Frost, and Jack Henkin. Abbott Laboratories, Abbott Park, IL, and Purdue University, West Lafayette, IN.

Thrombospondin-1 (TSP-1) is a naturally occurring inhibitor of angiogenesis that has been shown to block many of the functions of activated endothelial cells (EC) and to mitigate tumor growth and metastasis. The large size, the scarcity and the multiple biological activities of TSP-1 make it impractical for direct use in cancer therapy. The peptide, NAc-Gly-Val-Dlle-Thr-Arg-lle-ArgNHEt, a modified

fragment of TSP-1, was reported to inhibit EC migration in vitro (D. Dawson et al. Mol. Pharmacol., 55: 332-338, 1999). However, because of its short half-life in rodents this heptapeptide was not suitable for therapeutic use. To reduce its basicity and the likelihood of histamine release, we substituted Nva in place of the internal Arg. To increase metabolic stability we substituted Pro at the C- and Sar at the N-termini resulting in ABT-526, NAc-Sar-Gly-Val-Dlle-Thr-Nva-lle-Arg-ProNHEt. ABT-526 inhibited VEGF stimulated HMVEC migration with an IC₅₀ of 0.03 nM, abrogated EC tube formation in fibrin gels at concentrations from 100-200 nM and inhibited neovascularization in a mouse cornea angiogenesis model when delivered by sc or ip injection. Replacement of Dlle in ABT-526 with Dallolle provided ABT-510, which displayed similar antiangiogenic activity in vitro and also inhibited bFGF-induced neovascularization in a mouse cornea model when delivered continuously at 30 mg/kg/day. ABT-510 had increased water solubility and slower clearance in primates, compared with ABT-526. In summary ABT-526 and ABT-510 are two examples of a series of small peptide TSP-1 mimetics that inhibit angiogenesis in vitro and in vivo and have pharmacokinetic profiles potentially suitable for therapeutic use. ABT-510 is currently in Phase I clinical development.

#3666 Semisynthetic sulfaminoheparosansulfates from E. coli K5 polisaccharide are potent antitumor agents in B16-BL6 melanoma. Andreina Poggi, Cosmo Rossi, Anna Maria Naggi, Luisa Sturiale, and Benito Casu. Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy, and Istituto Scientifico G. Ronzoni, Milano, Italy.

Heparin and related glycosaminoglycans can inhibit cancer cell invasion, due to their pleiotropic effects. The aim of our study was: 1) to evaluate the antitumor and anticoagulant activities of a series of semysinthetic sulfaminoheparosansulfates (SAHS) obtained by chemical modifications of Kappa 5 polysaccharide of Escherichia coli, in comparison with heparin; 2) to better understand the role of chemical sulfation, in relation to antitumor activity.B16-BL6 melanoma cells (100.000 cells/mouse) were injected intravenously in C57BL6 mice, with or without SAHS, at the dose of 0.5 mg/mouse. The number of tumor lung nodules was significantly inhibited, as compared to controls, only by heparin (95.5 percent), SAHS-2 (84.2 percent) and SAHS-4 (91.1 percent), belonging to type B compounds, characterized by selective distribution of sulfated groups at 2-O or 3-O position of glucuronic acid residues. SAHS-4 showed a dose-dependent inhibition (IC-50 0.1 mg/mouse) similar to heparin (0.05 mg/mouse). The anticoagulant potency, measured by activated partial thromboplastin time (APTT) on mouse plasma, indicated a better and more prolonged effect of heparin, in comparison with SAHS-4. Accordingly, H but not SAHS-4 significantly inhibited B16BL6 lung colonies, given 1 h before tumor cells. SAHS-4 derived compounds with higher or lower molecular weight or affinity depleted of AT-III binding site were as active as the original compound, suggesting that the antitumor activity was not dependent on AT-III mediated inhibition of blood clotting. Interactions with other blood clotting inhibitors cannot be ruled out. The better activity of heparin may be due to a longer presence in the circulation and/or to a better ability to inhibit neoangiogenesis.

#3667 Structure-based design of bifunctional S1-site inhibitors of human urokinase-type plasminogen activator. Lorraine M. Deck, Justin Heynekamp, Louis E. Metzger IV, William Brown, M. Brown, Vince N. Montes, and David L. Vander Jagt. University of New Mexico School of Medicine, Albuquerque, NM.

The urokinase-type plasminogen activator (uPA) system consisting of the serine protease uPA, its receptor uPAR, and associated proteins plays a major role in metastasis through directional activation of plasminogen and other proteins required for degradation of extracellular matrix. High levels of uPA and uPAR in a number of cancers predict poor outcome. Both uPA and uPAR are attractive candidates for development of anti-metastatic drugs. In previous studies of serine esterases, we demonstrated that substituted 6-chloro-2-pyrones represented a class of active-site directed inhibitors which could be potent and selective. Molecular modeling studies indicated that these inhibitors would also bind to the active site of uPA which was confirmed experimentally. Since uPA demonstrates specificity for a specific arginine-X bond, we have taken a structure-based approach to the design of uPA inhibitors that include an arginino mimetic attached to the pyrone backbone. Modeling studies predict that these inhibitors are bifunctional active site inhibitors in which both the pyrone moiety and the arginino mimetic moiety will occupy the S1 subsite of uPA. In addition, these inhibitors have the potential to function as suicide substrates of uPA.

#3668 Synthesis of dihydropyridine derivates of genistein to inhibit glioblastoma invasion. Launa M. J. Lynch, Adeboye Adejare, and Alok Bhushan. Idaho State University, Department of Pharmaceutical Sciences, College of Pharmacy, Pocatello, ID.

Glioblastoma represents the major form of primary brain tumors. The growth of the tumor and its invasive character are responsible for poor patient prognosis. Previous studies have shown that genistein blocks glioblastoma invasion, by inhibiting PLCy-1 activation. The limitation of treating glioblastoma with genistein as a therapeutic agent could be due to its low distribution in the brain. To overcome this synthesize of dihydropyridine derivatives of isoflavones has been proposed. Based on a previous report dihydropyridine derivatives have been